Download up to 50 records using a credit card to purchase your current search results.
Purchase your current search resultsIf your search contains more than 50 records, you will receive only the first 50 based on the sorting chosen at the time of purchase. Downloads will contain all fields shown in the individual records, not only those visible on the search results page. If your search is 50 records or higher, a subscription might be a better option.
If your search contains fewer than 50 records, the balance cannot be used for a separate search.
Once you subscribe, you will be able to download your current search results. Downloads will contain all fields shown in the individual records, not only those visible on the search results page.
If the number of records in your search results exceeds the limit of your subscription tier, your download will include the maximum number based on the sorting chosen at the time of the download.
| Top 10 Current Parent Companies | Penalty Total (USD) | Number of Records |
|---|---|---|
| McKesson | $8,495,000,000 | 6 |
| Johnson & Johnson | $8,465,500,000 | 15 |
| Walgreens Boots Alliance | $7,490,073,583 | 10 |
| Cardinal Health | $6,970,000,000 | 8 |
| Cencora Inc. | $6,942,000,000 | 5 |
| CVS Health | $5,697,004,290 | 32 |
| Teva Pharmaceutical Industries | $5,434,929,633 | 12 |
| AbbVie | $5,397,449,298 | 16 |
| Walmart | $3,423,173,855 | 5 |
| Kroger | $3,025,871,559 | 9 |
| Top 10 Jurisdictions | Penalty Total (USD) | Number of Records |
|---|---|---|
| United States | $75,818,225,339 | 310 |
| United Kingdom | $2,079,243 | 7 |
| Australia | $207,948 | 1 |
Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
| Company | Current Parent | Current Parent Industry | Offense Category | Year | Jurisdiction | Penalty Amount (USD) |
|---|---|---|---|---|---|---|
| McKesson Corporation | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2021 | United States | $8,001,000,000 |
| AmerisourceBergen Corporation | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2021 | United States | $6,510,000,000 |
| Cardinal Health Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2021 | United States | $6,489,000,000 |
| Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $5,700,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | United States | $5,000,000,000 |
| CVS | CVS Health | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $5,000,000,000 |
| Teva Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $4,250,000,000 |
| Walmart Stores | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $3,100,000,000 |
| GlaxoSmithKline LLC | GSK plc | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | $3,000,000,000 |
| Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $2,370,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | United States | $2,200,000,000 |
| Mallinckrodt | Mallinckrodt | pharmaceuticals | controlled substances violation | 2020 | United States | $1,600,000,000 |
| Abbott Laboratories Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | $1,500,000,000 |
| Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2023 | United States | $1,370,000,000 |
| Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2024 | United States | $1,370,000,000 |
| Reckitt Benckiser Group plc | Reckitt Benckiser | household and personal care products | controlled substances violation | 2019 | United States | $1,347,000,000 |
| Merck, Sharp & Dohme | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | United States | $950,000,000 |
| Purdue Pharma LP | Purdue Pharma | pharmaceuticals | off-label or unapproved promotion of medical products | 2025 | United States | $900,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | $762,000,000 |
| Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $680,000,000 |
| McKinsey & Co. Inc. | McKinsey | business services | controlled substances violation | 2024 | United States | $650,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $612,000,000 |
| Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | $600,000,000 |
| McKinsey & Company | McKinsey | business services | off-label or unapproved promotion of medical products | 2021 | United States | $573,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $541,000,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | $520,000,000 |
| Google Inc. | Alphabet Inc. | information technology | off-label or unapproved promotion of medical products | 2011 | United States | $500,000,000 |
| Wyeth Pharmaceuticals Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | United States | $490,900,000 |
| CVS Health Corporation and CVS Pharmacy, Inc. | CVS Health | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $484,000,000 |
| GlaxoSmithKline | GSK plc | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $477,792,391 |
| Endo International plc | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $450,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | $422,500,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | United States | $410,000,000 |
| Abbott Laboratories | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $339,148,643 |
| Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | United States | $338,000,000 |
| Teva Pharmaceuticals, Ltd. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $313,343,793 |
| Indivior plc | Indivior PLC | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | United States | $300,000,000 |
| Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | United States | $285,000,000 |
| Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $278,826,499 |
| Purdue Pharma | Purdue Pharma | pharmaceuticals | controlled substances violation | 2019 | United States | $270,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $257,400,000 |
| Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | United States | $229,610,000 |
| Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $225,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $218,092,993 |
| Walmart Inc. | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $215,000,000 |
| Elan Corporation PLC | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | $203,000,000 |
| Merck Sharp & Dohme Corp. | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $201,975,000 |
| Reckitt Benckiser Group | Reckitt Benckiser | household and personal care products | controlled substances violation | 2019 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $200,000,000 |
| Allergan Finance LLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | United States | $200,000,000 |
| Endo Health Solutions Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | United States | $192,700,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | $181,000,000 |
| Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $173,000,000 |
| McKesson Corp. | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2022 | United States | $172,666,667 |
| Cardinal Health, Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2022 | United States | $172,666,667 |
| AmerisourceBergen Corp. | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2022 | United States | $172,666,667 |
| Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | United States | $164,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | $158,000,000 |
| McKesson Corporation | McKesson | wholesalers | controlled substances violation | 2017 | United States | $150,000,000 |
| Hikma Pharmaceuticals | Hikma Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | United States | $150,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | United States | $149,500,000 |
| Allergan Ltd. et al. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $134,200,000 |
| AmerisourceBergen | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2022 | United States | $133,333,333 |
| McKesson Corp. | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2022 | United States | $133,333,333 |
| Cardinal Health Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2022 | United States | $133,333,333 |
| Warner Chilcott PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | United States | $125,000,000 |
| Cardinal Health | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2024 | United States | $110,000,000 |
| Cencora | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2024 | United States | $110,000,000 |
| Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2025 | United States | $110,000,000 |
| Walgreens Boots Alliance, Inc. | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | United States | $102,000,000 |
| Janssen Pharmaceuticals | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $99,000,000 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | $95,000,000 |
| Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $95,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $88,258,694 |
| Indivior | Indivior PLC | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | United States | $86,000,000 |
| Scios Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | United States | $85,000,000 |
| Teva Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | controlled substances violation | 2019 | United States | $85,000,000 |
| Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $83,000,000 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | $81,000,000 |
| Walgreens Corporation | Walgreens Boots Alliance | retailing | controlled substances violation | 2013 | United States | $80,000,000 |
| Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $78,000,000 |
| CVS Pharmacy, Inc | CVS Health | retailing | controlled substances violation | 2010 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $77,600,000 |
| CVS Pharmacy Inc. | CVS Health | retailing | controlled substances violation | 2010 | United States | $77,600,000 |
| Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2024 | United States | $74,763,583 |
| Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | $72,500,000 |
| Teva Pharmaceuticals, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2023 | United States | $71,477,474 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | United States | $71,000,000 |
| Teva | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | United States | $70,281,867 |
| AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | United States | $68,500,000 |
| Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2023 | United States | $68,000,000 |
| Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $65,000,000 |
| Endo Health Solutions and Endo Pharmaceuticals | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | United States | $65,000,000 |
| Kroger Co. | Kroger | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $58,500,000 |
| Shire Pharmaceuticals LLC | Takeda Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | United States | $56,500,000 |
| Walmart | Walmart | retailing | off-label or unapproved promotion of medical products | 2024 | United States | $55,473,855 |
| Omnicare, Inc. | CVS Health | retailing | controlled substances violation | 2012 | United States | $50,000,000 |
| Endo Health Solutions | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | United States | $50,000,000 |
| Allergan PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2023 | United States | $48,666,145 |
| Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2024 | United States | $47,500,000 |
| Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | United States | $45,000,000 |
| Walmart | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | United States | $44,200,000 |
| Elan Corp. | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | United States | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Penalty totals are adjusted to avoid double-counting. $43,399,040 |
